Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

TCR-T

"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."

Trial Locations (1)

100039

The Fifth Medical Center of PLA General Hospital, Beijing

All Listed Sponsors
lead

Beijing 302 Hospital

OTHER

NCT05905731 - Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B | Biotech Hunter | Biotech Hunter